46 results
424B5
SEEL
Seelos Therapeutics Inc
30 Jan 24
Prospectus supplement for primary offering
6:05am
and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our employees
424B5
SEEL
Seelos Therapeutics Inc
30 Nov 23
Prospectus supplement for primary offering
4:58pm
. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our employees and parties conducting … condition, cause reputational harm with investors, our employees and parties conducting business with us and limit our access to debt and equity financing
424B5
SEEL
Seelos Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:06pm
and reduced news and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our … condition, cause reputational harm with investors, our employees and parties conducting business with us and limit our access to debt and equity financing
424B5
246r 5wizn
25 Sep 23
Prospectus supplement for primary offering
6:02am
424B5
7fo p7hx49oe7ppd
12 May 22
Prospectus supplement for primary offering
8:30am
424B5
rfhlq4klkksz0ok1uga
21 May 21
Prospectus supplement for primary offering
12:00am
424B5
9x322tnu
19 May 21
Prospectus supplement for primary offering
4:08pm